Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs. Dawes, P., Dimic, A., Genovese, M. C., van der Heijde, D., Jenkins, M., O'Brien, C., Oemar, B., Vencovsky, J., Weinblatt, M. WILEY-BLACKWELL. 2013: S198–S199
View details for Web of Science ID 000325359201454